SCHEMBL6790891

SCHEMBL6790891

COC(=O)c1cc(OC)c(OC)cc1NC(=O)/C=C(/C)c1ccc2cc(C)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.59
ALDH1A1 P00352 9/20 0.59
HPGD P15428 5/20 0.59
POLB P06746 1/20 0.53
GAA P10253 5/20 0.53
KMT2A Q03164 1/20 0.51
TERT O14746 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 2/20 0.48
HSD17B10 Q99714 4/20 0.48
HTT P42858 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GLA P06280 1/20 0.46
MAPT P10636 1/20 0.46
LTB4R Q15722 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786854 0.91 TERT (0.57) KDM4EALDH1A1HPGDGAAKMT2A
SCHEMBL6781951 0.90 KDM4E (0.60) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL6781638 0.90 TERT (0.61) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL6790307 0.85 TERT (0.58) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL6787614 0.82 KDM4E (0.53) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL6786762 0.82 KDM4E (0.53) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL7251979 0.82 KDM4E (0.48) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL6786628 0.81 TERT (0.58) KDM4EALDH1A1HPGDPOLBGAA
SCHEMBL4021468 0.81 TERT (0.71) KDM4EALDH1A1HPGDGAAKMT2A
SCHEMBL6784696 0.81 TERT (0.67) KDM4EALDH1A1HPGDGAATERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 KDM4E 1243/4885ALDH1A1 102/4885HPGD 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.